Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | F2 | P00734 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | VDR | P11473 | 3/20 | 0.44 |
| ▸ | XBP1 | P17861 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14866546 | 0.83 | GAA (0.44) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL2514063 | 0.82 | GAA (0.43) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL19351875 | 0.80 | GAA (0.42) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL25095038 | 0.80 | GAA (0.46) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL29565442 | 0.79 | ALDH1A1 (0.46) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL9425523 | 0.79 | ALDH1A1 (0.46) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL30660870 | 0.79 | ALDH1A1 (0.40) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL10851006 | 0.79 | ALDH1A1 (0.40) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL22954047 | 0.78 | GAA (0.47) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL9695998 | 0.77 | GAA (0.43) | GAAALDH1A1MAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-10927077-B2 | Process for preparing intermediate of anti-tumor drug niraparib and intermediate thereof | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2021-02-23 | — | — | US | disclosed |
| US-20200385350-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2020-12-10 | — | — | US | disclosed |
| US-20200048264-A1 | Processes for the Preparation of Acalabrutinib and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2020-02-13 | — | — | US | disclosed |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | SANDOZ AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | SANDOZ AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-8980326-B2 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8258190-B2 | Encapsulated contrast agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110092668-A1 | AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100324259-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100159020-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100136063-A1 | Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100022615-A1 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | ONCONOVA THERAPEUTICS, INC (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| EP-0928296-B1 | NO-COMPOUNDS FOR PSEUDO-LIVING RADICAL POLYMERIZATION | AKZO NOBEL NV (NL) | 2001-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | CYP51A1, CYP3A5, HCRTR2 | GAA 547/4885ALDH1A1 1386/4885MAPT 663/4885 |
| US-20100136063-A1 | Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides | IAPP, APP, TTR | GAA 95/4885ALDH1A1 4414/4885MAPT 6/4885 |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | GAA 218/4885ALDH1A1 269/4885MAPT 2245/4885 |
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | GAA 2168/4885ALDH1A1 4574/4885MAPT 4112/4885 |
| US-20110092668-A1 | AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS | IAPP, NGLY1, MSN | GAA 1249/4885ALDH1A1 4503/4885MAPT 1128/4885 |
| US-10927077-B2 | Process for preparing intermediate of anti-tumor drug niraparib and intermediate thereof | PARP1, PARP2, TOP2B | GAA 1074/4885ALDH1A1 893/4885MAPT 4724/4885 |
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | GAA 900/4885ALDH1A1 4667/4885MAPT 876/4885 |
| US-20200048264-A1 | Processes for the Preparation of Acalabrutinib and Intermediates Thereof | ACACB, ACACA, BTK | GAA 1412/4885ALDH1A1 587/4885MAPT 3365/4885 |
| US-20200385350-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | PARP1, PARP2, TOP2B | GAA 1074/4885ALDH1A1 893/4885MAPT 4724/4885 |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | LIPA, LPXN, CD47 | GAA 640/4885ALDH1A1 3588/4885MAPT 2491/4885 |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | DDT, ACHE, TPM3 | GAA 2283/4885ALDH1A1 391/4885MAPT 2103/4885 |
| US-20100022615-A1 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | CD40, TNFRSF9, NGFR | GAA 1375/4885ALDH1A1 2628/4885MAPT 3823/4885 |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | CYP51A1, CYP3A5, HCRTR2 | GAA 441/4885ALDH1A1 1560/4885MAPT 687/4885 |
| US-20100159020-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | GAA 757/4885ALDH1A1 4414/4885MAPT 102/4885 |
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | GAA 900/4885ALDH1A1 4667/4885MAPT 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.